IPH2101 was co-administered with lenalidomide, an agent that enhances NK cell activity by increasing the ligands of NK-cell-activating receptors, in phase I/II clinical trials with AML and MM patients [50,104,105] [clinicaltrials.gov ID: NCT01248455]. This evidence concerns the gene NCR2 and Miyoshi myopathy.